Skip to main content
Premium Trial:

Request an Annual Quote

Caliper, Invitrogen, Agilent, PerkinElmer, Sentigen, Bruker Daltonics, HealthLinx, Applera

Caliper to Market Invitrogen’s Fluorescent Kits for In Vivo Imaging
Invitrogen subsidiary Molecular Probes and Caliper Life Sciences plan to develop and distribute fluorescence labeling kits to work with Caliper’s in vivo imaging systems, Caliper said this week.
The kits are produced by Molecular Probes and will be marketed by Caliper. They use Invitrogen dyes to leverage the in vivo system to identify and tag particular antibodies, proteins, and peptides.
Caliper said each kit allows for three conjugations and will work on 60 to 90 small animals. The kits also allow for in vivo assessment of the spread of disease in real time, Caliper said.  
Financial terms of the deal were not released.

Agilent Opens Demonstration Facilities in US, India
Agilent Technologies has opened product demo facilities in the US and India, the company said last week.
Agilent opened a 5,000-square-foot product-demonstration center in Santa Clara, Calif., to exhibit its liquid and gas chromatography systems, mass spec systems, and microarray scanners. The facility also holds labs designed for proteomics and genomics, a wet lab, and conference spaces.
The company said it opened a similar center in Bangalore, India, last week, adding to others it has opened in France, the UK, and Germany.
Agilent said it plans to open another demo facility in Little Falls, Del. in 2007.
Chris van Ingen, Agilent’s president of Life Sciences and Chemical Analysis business, said the centers “provide a one-stop customer experience highlighting our entire portfolio of products and services.”

PerkinElmer Extends OneSource Service Deal with Schering-Plough
PerkinElmer has extended by three years a deal with Schering-Plough to implement its OneSource technology at four of the drug maker’s labs in New Jersey.
The deal extends a previous instrument, service, and lab-management agreement between the two companies.
Financial terms of the agreement were not released.

Sentigen Shareholders Approve Invitrogen Merger
Sentigen Holding last week said that its stockholders have approved its planned merger with Invitrogen.
Sentigen said it expects the deal to close “within the next several weeks.”
Invitrogen announced the $25.9-million agreement to acquire Sentigen, which includes its subsidiaries Sentigen Biosciences and Cell & Molecular Technologies, in August (see BioCommerce Week 9/6/2006).
The firm is betting that Sentigen's Tango assay system and division-arrested assay-ready cells will help it grow its own assay-development business by providing an additional way to screen G-protein coupled receptors and other “key” drug target classes.

Bruker Daltonics, HealthLinx File Patents on Biomarkers
Bruker Daltonics and HealthLinx have filed a joint PCT patent application to develop and market diagnostics based on their joint discovery of two biomarkers linked to pregnancy complications, HealthLinx said this week.
The tests will be based on Bruker’s ClinProt test, but HealthLinx said it will retain the rights to any ELISA/multiplex tests developed from these patents in the future.
HealthLinx, based in Melbourne, Australia, said that the two companies will share marketing rights for the test in the US and in Canada, but will split the international rights.
Bruker will handle Europe, the UK, Africa, and South America, while HealthLinx will have rights in Asia, Australia, and New Zealand.
HealthLinx added that the companies plan to share the development and marketing costs.
The companies have been engaged in a research collaboration for the past year, and are working to complete the second phase of trials. The biomarkers they discovered and hope to patent may be used to diagnose women who are predisposed to pregnancy complications such as preeclampsia, pre-term labor, miscarriage, and gestational diabetes.

Applera to Pay Quarterly Dividend
Applera has declared a quarterly dividend of $.0425 cents per share for its Applied Biosystems common stock.
The dividend is payable Jan. 2, 2007, to stockholders of record at the close of business on Dec. 1.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.